Speech-derived Digital Biomarkers Study

NCT06994767 — Not applicable, Completed, 150 participants, Hackensack Meridian Health

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Speech-derived Digital Biomarkers for Assessing Mild Cognitive Impairment and Alzheimer's Disease Diagnosis Accuracy

RegistryNCT06994767
StatusCompleted
PhaseNot applicable
Study typeInterventional; non randomized, parallel, masking: none, health services research
Enrollment150 (Actual)
SponsorHackensack Meridian Health (Other); collaborators: Canary Speech Inc.
ConditionsMild Cognitive Impairment (MCI), Alzheimer Disease
InterventionsThe Canary Application (Other)
Datesstart 2025-05-19, primary completion 2026-01-09, completion 2026-01-09, first posted 2025-05-29, last updated 2026-01-13
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Mild Cognitive Impairment (MCI) All trials for Alzheimer Disease All trials of The Canary Application

-Summary

The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD patients.

Expand all sections  ·  Collapse all

+Detailed description

The study aims to assess the sensitivity and specificity of an application that uses vocal biomarkers to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease. The application will use clinically validated survey instruments and voice recordings to determine the disease status of patients with MCI and Alzheimer's disease. The diagnosis developed by the application is the primary outcome variable. To determine the sensitivity and specificity, the application diagnosis will be compared against the physician's clinical diagnosis.

+Arms and interventions

ArmTypeInterventionsDescription
Mild Cognitive Impairment (MCI)ExperimentalOther: The Canary ApplicationPatients with a mild congitive impairment
Alzheimer's DiseaseExperimentalOther: The Canary ApplicationPatients with an Alzheimer's Disease diagnosis
Healthy VolunteersActive comparatorOther: The Canary ApplicationPatients without a diagnosis of MCI or Alzheimer's, or other types of dementia
  • The Canary Application (Other), also known as Validation: The CANARY application will use clinically validated survey instruments and voice recordings to measure user MCI status /Alzheimer's data. These tests are designed to evaluate a user's voice characteristics and potentially identify disease-specific patterns.

+Outcome measures

Primary outcomes

  • The primary objective of the study is to assess the sensitivity biomarkers in patients with MCI and AD diagnosis [Upon enrollment]: The CANARY application will use clinically validated survey instruments and voice recordings to analyze the data and determine the patient's MCI/ Alzheimer's disease diagnosis. The diagnosis developed by the application is the primary outcome variable. To determine the sensitivity, the application diagnosis will be compared against the clinical diagnosis of the physician.
  • The primary objective of the study is to assess the specificity of vocal biomarkers in patients with MCI and AD diagnosis [Upon enrollment]: The CANARY application will use clinically validated survey instruments and voice recordings to analyze the data and determine the patient's MCI/ Alzheimer's disease diagnosis. The diagnosis developed by the application is the primary outcome variable. To determine the specificity, the application diagnosis will be compared against the clinical diagnosis of the physician.

+Eligibility

Sex: All, ages: 50 Years to any

Inclusion Criteria:

* Males and females between the ages of 50 and above
* Willing and capable of participating in all aspects of the study
* Willing and capable of giving informed consent
* Diagnosis of MCI or Alzheimer's by the physician
* For the control group: Without diagnosis of MCI or Alzheimer's or other types of dementia
* Subjects are free of any medical condition(s) that, according to exclusion criteria, might audibly affect voice characteristics
* Subject must be able to speak and read with fluency in the English language.

Exclusion Criteria:

* All participants below 50 years
* Failure to provide informed consent
* Individuals with the following medical conditions will be excluded:

  i) Parkinson's disease ii) Huntington's disease iii) Cancer and active cancer treatments
* Persons with speech characteristics (heavy accents, slurring, stuttering, etc.) that would interfere with voice recording or voice analysis

+Locations (1)

FacilityCityCountryStatus
Hackensack University Medical CenterHackensack, New JerseyUnited States

+Publications

  • Martinez-Sanchez F, Meilan JJG, Carro J, Ivanova O. A Prototype for the Voice Analysis Diagnosis of Alzheimer's Disease. J Alzheimers Dis. 2018;64(2):473-481. doi: 10.3233/JAD-180037. PMID 29914025
  • Mueller KD, Hermann B, Mecollari J, Turkstra LS. Connected speech and language in mild cognitive impairment and Alzheimer's disease: A review of picture description tasks. J Clin Exp Neuropsychol. 2018 Nov;40(9):917-939. doi: 10.1080/13803395.2018.1446513. Epub 2018 Apr 19. PMID 29669461
  • Garcia AM, de Leon J, Tee BL, Blasi DE, Gorno-Tempini ML. Speech and language markers of neurodegeneration: a call for global equity. Brain. 2023 Dec 1;146(12):4870-4879. doi: 10.1093/brain/awad253. PMID 37497623
  • Sanborn V, Ostrand R, Ciesla J, Gunstad J. Automated assessment of speech production and prediction of MCI in older adults. Appl Neuropsychol Adult. 2022 Sep-Oct;29(5):1250-1257. doi: 10.1080/23279095.2020.1864733. Epub 2020 Dec 30. PMID 33377800
  • Vinod Subramanian, Namhee Kwon, Raymond Brueckner, Nate Blaylock, Henry O'Connell,

+Investigators